Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/920465/000156459021054269/ljpc-10q_20210930.htm
SEC Filings
LJPC Annual Reports
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report March 2020
10-K Annual Report March 2019
10-K Annual Report February 2018
10-K Annual Report February 2017
10-K Annual Report February 2016
10-K Annual Report March 2015
10-K Annual Report March 2014
10-K Annual Report March 2012
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report March 2020
10-K Annual Report March 2019
10-K Annual Report February 2018
10-K Annual Report February 2017
10-K Annual Report February 2016
10-K Annual Report March 2015
10-K Annual Report March 2014
10-K Annual Report March 2012
LJPC Quarterly Reports
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
LJPC Corporate News
Financial Exhibit
Other Events February 2022
Financial Exhibit
Other Events November 2021
Vote of Security Holders July 2021
Financial Exhibit
New Agreement January 2021
Ending Agreement
Financial Exhibit December 2020
Accountant Change
Financial Exhibit November 2020
Event for Officers October 2020
Event for Officers October 2020
Event for Officers September 2020
Ending Agreement August 2020
Financial Exhibit
Other Events
Other Events
February 2022
Financial Exhibit
Other Events
Other Events
November 2021
Vote of Security Holders
July 2021
Financial Exhibit
New Agreement
New Agreement
January 2021
Ending Agreement
Financial Exhibit
Financial Exhibit
December 2020
Accountant Change
Financial Exhibit
Financial Exhibit
November 2020
Event for Officers
October 2020
Event for Officers
October 2020
Event for Officers
September 2020
Ending Agreement
August 2020
Last10K.com | 10-Q Quarterly Report Thu Nov 04 2021
Document and Entity Information - shares | 9 Months Ended | |
|---|---|---|
Sep. 30, 2021 | Oct. 22, 2021 | |
| Cover [Abstract] | ||
| Document Type | 10-Q | |
| Document Quarterly Report | true | |
| Document Transition Report | false | |
| Entity File Number | 1-36282 | |
| Entity Registrant Name | LA JOLLA PHARMACEUTICAL COMPANY | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Tax Identification Number | 33-0361285 | |
| Entity Address, Address Line One | 201 Jones Road | |
| Entity Address, Address Line Two | Suite 400 | |
| Entity Address, City or Town | Waltham | |
| Entity Address, State or Province | MA | |
| Entity Address, Postal Zip Code | 02451 | |
| City Area Code | 617 | |
| Local Phone Number | 715-3600 | |
| Title of 12(b) Security | Common Stock, par value $0.0001 per share | |
| Trading Symbol | LJPC | |
| Security Exchange Name | NASDAQ | |
| Current Reporting Status | Yes | |
| Entity Interactive Data Current | Yes | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | false | |
| Shell Company | false | |
| Entity Common Stock, Shares Outstanding | 27,524,028 | |
| Entity Central Index Key | 0000920465 | |
| Document Period End Date | Sep. 30, 2021 | |
| Amendment Flag | false | |
| Document Fiscal Year Focus | 2021 | |
| Document Fiscal Period Focus | Q3 | |
| Current Fiscal Year End Date | --12-31 |
View differences made from one quarter to another to evaluate La Jolla Pharmaceutical Co's financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by La Jolla Pharmaceutical Co.
Assess how La Jolla Pharmaceutical Co's management team is paid from their Annual Proxy
La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
Tools
Rating
Learn More
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
-
Revenue - Product Highlight
Pursuant to the agreement: (i) the Company has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax; and (ii) the Company is entitled to receive potential commercial milestone payments of up to $109.5 million and royalties on net sales of GIAPREZA and XERAVA.
-
Other - Other Highlight
La Jolla has received an upfront cash payment of $22.5 million, less a 15% refundable withholding tax, and is entitled to receive potential commercial milestone payments 25 of up to $109.5 million and double-digit tiered royalty payments.
-
Financial - Expense Highlight
We expect our research and development expense to decrease in the near term.
-
Financial - Expense Highlight
During the three and nine months ended September 30, 2021, total research and development personnel expense, including share-based compensation expense, decreased compared to the same periods in 2020 as a result of: (i) reduced headcount; and (ii) one-time charges in 2020 resulting from: (a) a reduction of headcount from a Company-wide realignment in May 2020; and (b) a reduction of headcount combining La Jolla and Tetraphase personnel in July 2020.
-
Financial - Expense Highlight
During the three months ended September 30, 2021, total selling, general and administrative personnel expense decreased compared to the same period in 2020 primarily as a result of: (i) one-time charges in 2020 resulting from a reduction of headcount from combining La Jolla and Tetraphase personnel in July 2020; and (ii) reduced headcount.
-
Revenue - Product
The Company is eligible to...Read more
-
M & A - Other
On July 28, 2020, La...Read more
-
Financial - Expense
Personnel-related expense includes expense related...Read more
-
Financial - Expense
Personnel-related expense includes expense related...Read more
-
Revenue - Product
For each product covered by...Read more
-
Other - Other
We can provide no assurance...Read more
-
Revenue - Product
La Jolla's license and other...Read more
-
Financial - Expense
We do not expect our...Read more
-
Financial - Expense
La Jolla's net cash provided...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Shareholders' Deficit (Unaudited)
Acquisition Of Tetraphase Pharmaceuticals, Inc
Acquisition Of Tetraphase Pharmaceuticals, Inc (Tables)
Acquisition Of Tetraphase Pharmaceuticals, Inc - Summary Of Purchase Price Allocation As Of Acquisition Date (Details)
Acquisition Of Tetraphase Pharmaceuticals, Inc. Additional Information (Details)
Balance Sheet Details
Balance Sheet Details (Tables)
Balance Sheet Details - Additional Information (Details)
Balance Sheet Details - Property Plant And Equipment (Details)
Balance Sheet Details - Schedule Of Intangible Assets, Net (Details)
Balance Sheet Details - Schedule Of Inventory (Details)
Balance Sheet Details - Schedule Of Other Noncurrent Liabilities (Details)
Balance Sheet Details - Schedule Of Prepaid Expenses And Other Current Assets (Details)
Balance Sheet Details - Summary Of Accrued Expenses (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies
Basis Of Presentation And Summary Of Significant Accounting Policies (Policies)
Basis Of Presentation And Summary Of Significant Accounting Policies (Tables)
Basis Of Presentation And Summary Of Significant Accounting Policies - Additional Information (Details)
Basis Of Presentation And Summary Of Significant Accounting Policies - Schedule Of Concentration Risk (Details)
Business
Business - Additional Information (Details)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Details)
Commitments And Contingencies - Future Minimum Lease Payments Excluding Operating Costs (Details)
Company-Wide Realignment
Company-Wide Realignments - Additional Information (Details)
Deferred Royalty Obligation
Deferred Royalty Obligation - Additional Information (Details)
Earnings (Loss) Per Share
Earnings (Loss) Per Share - Additional Information (Details)
Equity Incentive Plans
Equity Incentive Plans (Tables)
Equity Incentive Plans - Narrative (Details)
Equity Incentive Plans - Share-Based Compensation Expense (Details)
Equity Incentive Plans - Stock Option Activity (Details)
Equity Incentive Plans - Stock Option Activity (Parenthetical) (Details)
Income Taxes
Income Taxes - Additional Information (Details)
License Agreements
License Agreements - Additional Information (Details)
Other Income-Related Party
Other Income-Related Party - Additional Information (Details)
Shareholders Equity
Shareholders' Equity - Additional Information (Details)
Subsequent Event
Material Contracts, Statements, Certifications & more
La Jolla Pharmaceutical Co provided additional information to their SEC Filing as exhibits
Ticker: LJPC
CIK: 920465
Form Type: 10-Q Quarterly Report
Accession Number: 0001564590-21-054269
Submitted to the SEC: Thu Nov 04 2021 8:31:19 AM EST
Accepted by the SEC: Thu Nov 04 2021
Period: Thursday, September 30, 2021
Industry: Biological Products No Disgnostic Substances
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/ljpc/0001564590-21-054269.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
SEC Filing Financial Summary
Excel Download
Loading SEC Filing Financial Summary...